Leah Nylen

June 24, 2022

Antitrust reporter Leah Nylen has been with Bloomberg News since April of this year. Before joining Bloomberg, Leah covered antitrust and investigations for Politico Pro. Leah spent eight years covering antitrust at MLex prior.

She has also worked for Bloomberg and Congressional Quarterly and was selected as an Abe Journalist Fellow in 2014 for a reporting project in Japan on price-fixing cartels and cartel deterrence policies. Leah holds a bachelor’s degree from the University of Virginia and a master’s degree from Northwestern University.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor